US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Anteris Technologies Global Corp. - Common Stock (NQ:AVR)

6.420 +0.320 (+5.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anteris Technologies Global Corp. - Common Stock

< Previous 1 2 Next >
News headline image
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris to Present at September Healthcare Investor Conferences
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces Results for the Second Quarter of 2026
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the First Quarter of 2026
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Reports 2025 Financial Results and Provides Corporate Update
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the Third Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the Second Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities 
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the First Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year 
From Anteris Technologies Global Corp.
Via GlobeNewswire
< Previous 1 2 Next >